Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): An open-label, multicenter, prospective phase 3b study

on behalf of STRATO Investigators

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Tremor is a common side effect of tacrolimus correlated with peak-dose drug concentration. LCPT, a novel, once-daily, extended-release formulation of tacrolimus, has a reduced Cmax with comparable AUC exposure, requiring a ~30% dose reduction vs. immediate-release tacrolimus. In this phase 3b study, kidney transplant recipients (KTR) on a stable dose of tacrolimus and with a reported clinically significant tremor were offered a switch to LCPT. Tremor pre- and seven d post-conversion was evaluated by independent, blinded movement disorder neurologists using the Fahn-Tolosa-Marin (FTM) scale and by an accelerometry device; patients completed the QUEST (quality of life in essential tremor) and the Patient Global Impression of Change. There were 38 patients in the mITT population. A statistically and clinically significant improvement in tremor (FTM score, amplitude as measured by the accelerometry device and QOL [p-values < 0.05]) resulted post-conversion. Change in QUEST was significantly (p = 0.006) correlated (R = 0.44) with change in FTM; 78.9% of patients reported an improvement after switching to LCPT (p < 0.0005). To our knowledge this is the first trial in KTR that utilizes a sophisticated and reproducible measurement of tremor. Results suggest LCPT is associated with clinically meaningful improvement of hand tremor and may be an alternative management approach in lieu of further dose reduction of immediate-release tacrolimus for patients experiencing tremor.

Original languageEnglish (US)
Pages (from-to)796-805
Number of pages10
JournalClinical Transplantation
Volume29
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Tremor
Tacrolimus
Transplants
Kidney
Accelerometry
Essential Tremor
Quality of Life
Equipment and Supplies
Movement Disorders
Area Under Curve
Hand
Pharmaceutical Preparations
Population

Keywords

  • Adverse events
  • Envarsus
  • Extended-release
  • Kidney transplantation
  • LCP-Tacro
  • MeltDose
  • Prograf
  • Tacrolimus
  • Tremor

ASJC Scopus subject areas

  • Transplantation

Cite this

Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO) : An open-label, multicenter, prospective phase 3b study. / on behalf of STRATO Investigators.

In: Clinical Transplantation, Vol. 29, No. 9, 01.09.2015, p. 796-805.

Research output: Contribution to journalArticle

@article{e98aaa8294714ef293b28228a20414e6,
title = "Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): An open-label, multicenter, prospective phase 3b study",
abstract = "Tremor is a common side effect of tacrolimus correlated with peak-dose drug concentration. LCPT, a novel, once-daily, extended-release formulation of tacrolimus, has a reduced Cmax with comparable AUC exposure, requiring a ~30{\%} dose reduction vs. immediate-release tacrolimus. In this phase 3b study, kidney transplant recipients (KTR) on a stable dose of tacrolimus and with a reported clinically significant tremor were offered a switch to LCPT. Tremor pre- and seven d post-conversion was evaluated by independent, blinded movement disorder neurologists using the Fahn-Tolosa-Marin (FTM) scale and by an accelerometry device; patients completed the QUEST (quality of life in essential tremor) and the Patient Global Impression of Change. There were 38 patients in the mITT population. A statistically and clinically significant improvement in tremor (FTM score, amplitude as measured by the accelerometry device and QOL [p-values < 0.05]) resulted post-conversion. Change in QUEST was significantly (p = 0.006) correlated (R = 0.44) with change in FTM; 78.9{\%} of patients reported an improvement after switching to LCPT (p < 0.0005). To our knowledge this is the first trial in KTR that utilizes a sophisticated and reproducible measurement of tremor. Results suggest LCPT is associated with clinically meaningful improvement of hand tremor and may be an alternative management approach in lieu of further dose reduction of immediate-release tacrolimus for patients experiencing tremor.",
keywords = "Adverse events, Envarsus, Extended-release, Kidney transplantation, LCP-Tacro, MeltDose, Prograf, Tacrolimus, Tremor",
author = "{on behalf of STRATO Investigators} and Anthony Langone and Steinberg, {Steven M.} and Roberto Gedaly and Chan, {Laurence K.} and Tariq Shah and Sethi, {Kapil D.} and Vincenza Nigro and Morgan, {John Christopher}",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/ctr.12581",
language = "English (US)",
volume = "29",
pages = "796--805",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO)

T2 - An open-label, multicenter, prospective phase 3b study

AU - on behalf of STRATO Investigators

AU - Langone, Anthony

AU - Steinberg, Steven M.

AU - Gedaly, Roberto

AU - Chan, Laurence K.

AU - Shah, Tariq

AU - Sethi, Kapil D.

AU - Nigro, Vincenza

AU - Morgan, John Christopher

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Tremor is a common side effect of tacrolimus correlated with peak-dose drug concentration. LCPT, a novel, once-daily, extended-release formulation of tacrolimus, has a reduced Cmax with comparable AUC exposure, requiring a ~30% dose reduction vs. immediate-release tacrolimus. In this phase 3b study, kidney transplant recipients (KTR) on a stable dose of tacrolimus and with a reported clinically significant tremor were offered a switch to LCPT. Tremor pre- and seven d post-conversion was evaluated by independent, blinded movement disorder neurologists using the Fahn-Tolosa-Marin (FTM) scale and by an accelerometry device; patients completed the QUEST (quality of life in essential tremor) and the Patient Global Impression of Change. There were 38 patients in the mITT population. A statistically and clinically significant improvement in tremor (FTM score, amplitude as measured by the accelerometry device and QOL [p-values < 0.05]) resulted post-conversion. Change in QUEST was significantly (p = 0.006) correlated (R = 0.44) with change in FTM; 78.9% of patients reported an improvement after switching to LCPT (p < 0.0005). To our knowledge this is the first trial in KTR that utilizes a sophisticated and reproducible measurement of tremor. Results suggest LCPT is associated with clinically meaningful improvement of hand tremor and may be an alternative management approach in lieu of further dose reduction of immediate-release tacrolimus for patients experiencing tremor.

AB - Tremor is a common side effect of tacrolimus correlated with peak-dose drug concentration. LCPT, a novel, once-daily, extended-release formulation of tacrolimus, has a reduced Cmax with comparable AUC exposure, requiring a ~30% dose reduction vs. immediate-release tacrolimus. In this phase 3b study, kidney transplant recipients (KTR) on a stable dose of tacrolimus and with a reported clinically significant tremor were offered a switch to LCPT. Tremor pre- and seven d post-conversion was evaluated by independent, blinded movement disorder neurologists using the Fahn-Tolosa-Marin (FTM) scale and by an accelerometry device; patients completed the QUEST (quality of life in essential tremor) and the Patient Global Impression of Change. There were 38 patients in the mITT population. A statistically and clinically significant improvement in tremor (FTM score, amplitude as measured by the accelerometry device and QOL [p-values < 0.05]) resulted post-conversion. Change in QUEST was significantly (p = 0.006) correlated (R = 0.44) with change in FTM; 78.9% of patients reported an improvement after switching to LCPT (p < 0.0005). To our knowledge this is the first trial in KTR that utilizes a sophisticated and reproducible measurement of tremor. Results suggest LCPT is associated with clinically meaningful improvement of hand tremor and may be an alternative management approach in lieu of further dose reduction of immediate-release tacrolimus for patients experiencing tremor.

KW - Adverse events

KW - Envarsus

KW - Extended-release

KW - Kidney transplantation

KW - LCP-Tacro

KW - MeltDose

KW - Prograf

KW - Tacrolimus

KW - Tremor

UR - http://www.scopus.com/inward/record.url?scp=84940958880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940958880&partnerID=8YFLogxK

U2 - 10.1111/ctr.12581

DO - 10.1111/ctr.12581

M3 - Article

C2 - 26113208

AN - SCOPUS:84940958880

VL - 29

SP - 796

EP - 805

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 9

ER -